309 related articles for article (PubMed ID: 29096894)
21. LC-MS/MS-based targeted proteomics quantitatively detects the interaction between p53 and MDM2 in breast cancer.
Zhang W; Zhong T; Chen Y
J Proteomics; 2017 Jan; 152():172-180. PubMed ID: 27826076
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
Huang K; Tang Y; He L; Dai Y
Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
[TBL] [Abstract][Full Text] [Related]
23. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
24. Negative cross talk between NFAT1 and Stat5 signaling in breast cancer.
Zheng J; Fang F; Zeng X; Medler TR; Fiorillo AA; Clevenger CV
Mol Endocrinol; 2011 Dec; 25(12):2054-64. PubMed ID: 21964595
[TBL] [Abstract][Full Text] [Related]
25. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
26. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
Xiong J; Li J; Yang Q; Wang J; Su T; Zhou S
Breast Cancer Res; 2017 Mar; 19(1):27. PubMed ID: 28274247
[TBL] [Abstract][Full Text] [Related]
27. p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases.
Thomasova D; Mulay SR; Bruns H; Anders HJ
Neoplasia; 2012 Dec; 14(12):1097-101. PubMed ID: 23308042
[TBL] [Abstract][Full Text] [Related]
28. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
29. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer.
Agrawal A; Yang J; Murphy RF; Agrawal DK
Exp Mol Pathol; 2006 Oct; 81(2):115-22. PubMed ID: 16919268
[TBL] [Abstract][Full Text] [Related]
31. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
[TBL] [Abstract][Full Text] [Related]
32. Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review.
Shaikh MF; Morano WF; Lee J; Gleeson E; Babcock BD; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2016 Dec; 46(6):627-634. PubMed ID: 27993876
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in validating MDM2 as a cancer target.
Rayburn ER; Ezell SJ; Zhang R
Anticancer Agents Med Chem; 2009 Oct; 9(8):882-903. PubMed ID: 19538162
[TBL] [Abstract][Full Text] [Related]
34. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
35. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
36. Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen.
Qin JJ; Li X; Wang W; Zi X; Zhang R
Front Pharmacol; 2017; 8():917. PubMed ID: 29311926
[TBL] [Abstract][Full Text] [Related]
37. Small-molecule inhibitors of the p53-MDM2 interaction.
Vu BT; Vassilev L
Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
[TBL] [Abstract][Full Text] [Related]
38. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
[TBL] [Abstract][Full Text] [Related]
39. TIS21
Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
[TBL] [Abstract][Full Text] [Related]
40. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
